Jeremiah Olorunjuwon Olugbami

This paper develops dual-acting inhibitors combining estrogen receptor ligands with KDM inhibitors, showing potent anti-proliferative effects against both ER+ and ER- breast cancer cells in xenograft models.

This study identifies KDM inhibition as a key anticancer mechanism of DFP and demonstrates PROTACs as a strategy to enhance its therapeutic potential.

This paper identifies a novel HDAC inhibitor, STR-V-53, that effectively targets HCC and enhances immunotherapy responses in mouse models.